Michael Barry
Analyst · Sidoti & Company. Please go ahead
Thank you, Dana. Good morning, everyone. Joining me today are Mary Hall, our CFO; and Robert Traub, our General Counsel. After my comments, Mary will provide the details around the financials, and then we'll address any questions that you may have. We also have slides for our conference call. You can find them in the Investor Relations section of our website at www.quakerchem.com. I'll now start off now with some remarks about the first quarter. I'm pleased we have delivered another good quarter, despite some market challenges. The quarter's results were largely driven by two major factors. The first was sales and the second was gross margins. Let me start with the margins. Since mid-2016, we have been in a generally rising raw material cost environment. And as we have discussed in the past with raw materials, there's a lag effect between changes in our raw material costs and adjustments to our product pricing. On the last conference call, our expectation was that gross margins would begin to increase in the first quarter and they did. While raw materials continue to rise sequentially from the fourth quarter, our previous price increases were enough to begin to turn the tide and we saw our gross margin increase. The good news is that we expect our gross margins to trend upwards over the next few quarters and expect that for 2018, our gross margins will be around 36%. While we expect certain raw materials to continue to increase especially in the first part of the year, we also have price initiatives in place to offset the raw material cost increases where necessary. While we continue to experience more of this lag effect that we talked about in the past, we are making good progress and that is the reason for our higher margin expectations. So we do expect our margins to continue to increase, but the exact timing of when we will reach our 37% target is hard to predict. Now let me move on to sales. Our sales increase 9% versus prior year with 6% of the increase coming from foreign exchange. Let me now give you some additional color on our region's performance for the quarter. Our biggest segment, North America showed a sales increase of 5% with volume growth near 2% and the remainder mainly due to price increases. Our European or EMEA region showed a 15% increase with exchange rates being the primary reason. We did see a volume decrease of 6% being offset by primarily higher prices. The EMEA volumes in the first quarter were actually quite strong, but the prior year volumes were unusually high due to atypical sales pattern. In our Asia-Pacific region, our sales increased 8% with higher volumes being the primary driver. And for the seventh quarter in a row, we're happy to report the South America showed good revenue growth. The 11% growth in South America sales was primarily due to volume growth, as well as price increases. One way to look at our market share gains is to look at our overall organic product volume growth in the quarter and compare that to the underlying production growth in our base markets of global steel and auto. We estimate that our overall volume growth excluding EMEA due to the atypical sales in Q1 2017 was 4% as compared to the underlying growth in our base markets which we estimate at 2%. We believe this spread of 2% is indicative of our share gains and is due to our commitment of our customer intimacy model. Specifically, we put our customer needs first as our top priority providing a strong service and business solutions. I believe this approach continues to differentiate us in the marketplace. In addition, we continue to invest in many other initiatives in our existing business lines in each of our regions that will extend our competitive advantage and help us gain further share, which includes growing our recently-acquired technologies around the globe. And as mentioned in the past using the baseball analogy, I see each initiatives as singles and our goals to hit many singles to produce multiple runs and thereby show continuing growth even in the challenging market. One item worth mentioning that I believe was worth a number of singles was our recent purchase of our partner's interest in our India JV. We now have 100% ownership in our India business which we believe will have strong inherent growth characteristics in our base markets for the foreseeable future. So in summary for the quarter, despite the challenge we faced with higher raw material cost, we were able to grow our adjusted EBITDA by 9% and our non-GAAP earnings by 17%. In a nutshell, we were able to do this by growing in our base markets, taking share in the marketplace, beginning to increase our gross margins and continuing to leverage our SG&A. I now like to make a few remarks about our combination with Houghton International. Since our announcement in the April of last year, we've been proceeding down numerous paths to close the deal. The one path that largely determines timing of the close is the regulatory review process. To date, we have received approval from China and Australia. The U.S. FTC and European Commission are still in the process of their reviews and we do expect to divest a small number of product lines, but the current expected remedies are consistent with our regional expectations. We have expected to close in the second quarter once we filed with the European Commission in Q1. We were going down a two-step path with the European Commission, a first, gaining approval on the remedy from the European Commission and then after that, getting approval for the buyer. As we were going down this path and based on discussions with the European Commission, we decided that it would be best to go for one approval for both the remedy and the buyer at the same time. Though we stopped the filing that was under way and we're now in the process of choosing the buyer for the divested product lines. We expected buyer to be chosen in the second quarter and expect to file with the European Commission for both the approval and the remedy of the buyer. The good news is that we're in general agreement with the regulatory authorities on what remedies have to be made. We currently expect regulatory approval from both the U.S. Federal Trade Commission and the European Commission, as well as the closing to be completed over the next few months. As we said in the past, we are excited about this combination as it will essentially double the size of the company, enable continued above-market growth through group cross-selling opportunities and provide at least $45 million in cost energies. Our intent is to have an investor call after the closing and provide an updated view of the new company as well as our expected synergies. So, I believe 2018 will be another good year for Quaker. We expect to close the combination with Houghton, see gross margin improvement and get benefits of the tax reform. In addition, we expect to see growth in our end markets in those regions in the world and we expect to continue to grow above the market as we have done historically through our growth initiatives and market share gains. In closing, I want to thank all of our associates whose dedication and expertise helps to create value for our customers and shareholders and differentiate Quaker in the marketplace. People are everything in our business and by far our most valuable asset. I am very happy with our Quaker team and continue to be excited about the upcoming combination with the Houghton International team. And now I'll turn it over to Mary Hall, our CFO so that she can provide you with more details behind the financials. Once Mary has completed her comments with the financials of the quarter, we will address any questions that you may have. Mary?